- Revenue grew 15% year-on-year to Rs. 176.7 crores in Q1 FY25
- Advanced Pharmaceutical Intermediates segment grew 16.6% to Rs. 135 crores
- Specialty Chemicals segment grew 10% to Rs. 42 crores
- Gross margin improved to 42.1% from 40% in Q4 FY24
- EBITDA margin declined to 16.7% from 22.1% in Q1 FY24
- Establishing Enchem AMI Organics as a subsidiary for electrolyte manufacturing
- Expanding electrolyte additives capacity to 2,000 metric tonnes
- Developing 8 new electrolyte additives beyond VC and FEC
- Expanding into Japan market after successful PMDA inspection
- Promoting new molecules from Baba Fine Chemicals to Korean and Japanese customers
- Ankleshwar plant expansion on track - remaining 2 blocks to be completed by Q2 FY25
- 16 MW solar power plant project initiated, expected completion by Q2 FY25
- Electrolyte additives capacity expansion on track for completion by end of FY25
- Targeting 25% revenue growth for FY25
- Aiming to reach 20%+ EBITDA margins by Q3/Q4 FY25
- Expecting asset turnover of 3-4x for Ankleshwar plant at full utilization
- Confident of meeting 25% growth guidance for FY25
- Expecting sequential growth in coming quarters
- Fermion contract to fully ramp up in FY26
- Peak sales for Apixaban and Rivaroxaban expected in FY26
- 15% YoY revenue growth despite industry challenges, driven by pharma segment
- Margins under pressure but expected to improve with higher utilization and better product mix
- New growth drivers like electrolytes, Japan expansion, and CDMO contracts in pipeline
Subscribe To Our Free Newsletter |